Document is current
Any future updates will be listed below
-
Authors
Pérez-Then, Eddy
Lucas, Carolina http://orcid.org/0000-0003-4590-2756
Monteiro, Valter Silva http://orcid.org/0000-0003-1785-6713
Miric, Marija
Brache, Vivian
Cochon, Leila
Vogels, Chantal B. F. http://orcid.org/0000-0003-0027-6480
Malik, Amyn A.
De la Cruz, Elena
Jorge, Aidelis
De los Santos, Margarita
Leon, Patricia
Breban, Mallery I. http://orcid.org/0000-0002-8976-9988
Billig, Kendall
Yildirim, Inci http://orcid.org/0000-0002-8631-0020
Pearson, Claire
Downing, Randy
Gagnon, Emily
Muyombwe, Anthony
Razeq, Jafar
Campbell, Melissa
Ko, Albert I. http://orcid.org/0000-0001-9023-2339
Omer, Saad B. http://orcid.org/0000-0002-5383-3474
Grubaugh, Nathan D. http://orcid.org/0000-0003-2031-1933
Vermund, Sten H. http://orcid.org/0000-0001-7289-8698
Iwasaki, Akiko http://orcid.org/0000-0002-7824-9856
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute (N/A)
Pew Charitable Trusts (N/A)
- License Information
-
More Information
Article History
Received: 4 January 2022
Accepted: 18 January 2022
First Online: 20 January 2022
Competing interests
: A.I. served as a consultant for RIGImmune, Xanadu and Revelar Biotherapeutics. I.Y. reported being a member of the mRNA-1273 Study Group and has received funding to her institution to conduct clinical research from BioFire, MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Novavax, Sanofi-Pasteur and Micron. N.D.G. is a consultant for Tempus Labs to develop infectious disease diagnostic assays. A.I.K. serves as an expert panel member for Reckitt Global Hygiene Institute, a scientific advisory board member for Revelar Biotherapeutics and a consultant for Tata Medical and Diagnostics and Regeneron Pharmaceuticals, and has received grants from Merck, Regeneron Pharmaceuticals, and Tata Medical and Diagnostics for research related to COVID-19 outside of the submitted work. All other authors declare no competing interests.
